ASX Release

03 April 2024

AROVELLA EXPANDS SCIENTIFIC ADVISORY BOARD WITH THE APPOINTMENT OF PROFESSOR GIANPIETRO DOTTI

Highlights:

- **Arovella is honoured to appoint CAR-iNKT cell pioneer Professor Gianpietro Dotti to its Scientific Advisory Board**
- **Professor Dotti has spent more than 20 years using his medical and scientific background to use gene-modified immune cells to treat blood cancers and solid tumours**
- **Professor Dotti has played an integral role developing CAR-iNKT cell therapeutics in solid tumours in paediatric patients**

MELBOURNE, AUSTRALIA 03 April 2024: Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell therapy platform, is delighted to welcome Professor Gianpietro Dotti to its Scientific Advisory Board.

Arovella is one of only several companies globally developing CAR-iNKT cells for cancer treatment. Professor Gianpietro Dotti's appointment strengthens Arovella's expertise in using CAR-iNKT cells to treat blood cancers and solid tumours. Professor Dotti is a pioneer and one of the first individuals to create CAR-iNKT cell strategies for cancer treatment. He has been involved in the development of two products using CAR-iNKT cells that have been used in blood cancer patients and paediatric patients with neuroblastoma.

Professor Dotti has spent more than twenty years using his medical and scientific training to create engineered immune cells for cancer treatment. His research has led to more than 200 peer-reviewed articles, and he has consistently received the Highly Cited Researchers (Top 1%) award from Web of Science, Clarivate Analytics in 2020, 2021, 2022, and 2023.

Professor Dotti received his medical degree from the University of Milan, Italy and completed his clinical training and Board certification in haematology from the University of Parma. He completed his post-doctoral fellowship at the Center for Cell and Gene Therapy at the Baylor College of Medicine in Houston, Texas. Professor Dotti is currently a Professor of Microbiology and Immunology, and the Director of the Cellular Immunotherapy Program at Lineberger Comprehensive Cancer Center at the University of North Carolina.

Arovella's CEO and MD, Dr Michael Baker, commented: "We are honoured and grateful to have someone of Giampietro's calibre join our Scientific Advisory Board. He is a remarkable individual, and his scientific involvement in developing and manufacturing CAR-iNKT cells will be a valuable addition to Arovella and our ongoing programs, which are now funded to take into clinical trials. We warmly welcome Gianpietro to Arovella's Scientific Advisory Board."

Release authorised by the Managing Director and Chief Executive Officer of Arovella Therapeutics Limited.

Dr Michael Baker
Chief Executive Officer & Managing Director
Arovella Therapeutics Ltd
Tel +61 (0) 403 468 187
investor@arovella.com

NOTES TO EDITORS:

About Arovella Therapeutics Ltd

Arovella Therapeutics Ltd (ASX: ALA) is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. Arovella's lead product is ALA-101. ALA-101 consists of CAR19-iNKT cells that have been modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19. CD19 is an antigen found on the surface of numerous cancer types. Arovella is also expanding into solid tumour treatment through its CLDN18.2-targeting technology licensed from Sparx Group. iNKT cells also contain an invariant T cell receptor (iTCR) that targets α-GalCer bound CD1d, another antigen found on the surface of several cancer types. ALA-101 is being developed as an allogeneic cell therapy, which means it can be given from a healthy donor to a patient.

Glossary: iNKT cell – invariant Natural Killer T cells; **CAR** – Chimeric Antigen Receptor that can be introduced into immune cells to target cancer cells; **TCR** – T cell receptors are a group of proteins found on immune cells that recognise fragments of antigens as peptides bound to MHC complexes; **B-cell lymphoma** – A type of cancer that forms in B cells (a type of immune system cell); **CD1d** – Cluster of differentiation 1, which is expressed on some immune cells and cancer cells; **aGalCer** – alpha-galactosylceramide is a specific ligand for human and mouse natural killer T cells. It is a synthetic glycolipid.

For more information, visit www.arovella.com.

This announcement contains certain statements which may constitute forward-looking statements or information ("forward-looking statements"), including statements regarding negotiations with third parties and regulatory approvals. These forward-looking statements are based on certain key expectations and assumptions, including assumptions regarding the actions of third parties and financial terms. These factors and assumptions are based upon currently available information, and the forward-looking statements herein speak only of the date hereof. Although the expectations and assumptions reflected in the forward-looking statements are reasonable in the view of the Company's directors and management, reliance should not be placed on such statements as there is no assurance that they will prove correct. This is because forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. These risks include but are not limited to: uncertainties and other factors that are beyond the control of the Company; global economic conditions; the risk associated with foreign currencies; and risk associated with securities market volatility. The Company assumes no obligation to update any forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements, except as required by Australian securities laws and ASX Listing Rules.